# Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

> **NCT01929759** · NA · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- HIV Disease

## Interventions

- **DRUG:** Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)

## Key facts

- **NCT ID:** NCT01929759
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929759, "Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01929759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*